英文名稱 | Tofacitinib Citrate | Tasocitinib Citrate | CP-690550 Citrate |
---|---|
中文名稱 | 枸櫞酸托法替尼丨枸櫞酸托法替布 |
CAS號(hào) | 540737-29-9 |
分子式 | C16H20N6O.C6H8O7 |
分子量 | 504.49 |
外觀 | White to off-white powder |
儲(chǔ)存條件 | 4°C, sealed storage, away from moisture and light |
規(guī)格 | 庫存 | 目錄價(jià) | 會(huì)員專享價(jià) | 數(shù)量 | |
---|---|---|---|---|---|
暫無牌價(jià)信息,您可以發(fā)送詢價(jià),我們會(huì)盡快給你回復(fù)。 |
英文名稱 | Tofacitinib Citrate | Tasocitinib Citrate | CP-690550 Citrate |
---|---|
中文名稱 | 枸櫞酸托法替尼丨枸櫞酸托法替布 |
CAS號(hào) | 540737-29-9 |
分子式 | C16H20N6O.C6H8O7 |
分子量 | 504.49 |
外觀 | White to off-white powder |
儲(chǔ)存條件 | 4°C, sealed storage, away from moisture and light |
Tofacitinib, also known as tasocitinib, CP-690550, is a Janus kinase (JAK) inhibitor. Tofacitinib modulates the signaling pathway at the point of JAKs, preventing the phosphorylation and activation of STATs. JAK enzymes transmit cytokine signaling through pairing of JAKs (e.g., JAK1/JAK3, JAK1/JAK2, JAK1/TyK2, JAK2/JAK2). Tofacitinib inhibited the in vitro activities of JAK1/JAK2, JAK1/JAK3, and JAK2/JAK2 combinations with IC50 of 406, 56, and 1377 nM, respectively.
PMID: 29458040 DOI: 10.1016/j.ejphar.2018.02.022
PMID: 22899318 DOI: 10.1002/art.34649
PMID: 19053756 PMCID: PMC2660606 DOI: 10.1021/jm801142b
Tofacitinib suppresses antibody responses to protein therapeutics in murine hosts.
PMID: 24890727 PMCID: PMC4106678 DOI: 10.4049/jimmunol.1400063